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a b s t r a c t
The HIV-1 protein Vpr enhances macrophage infection, triggers G2 cell cycle arrest, and targets cells for
NK-cell killing. Vpr acts through the CRL4DCAF1 ubiquitin ligase complex to cause G2 arrest and trigger
expression of NK ligands. Corresponding ubiquitination targets have not been identiﬁed. UNG2 and
SMUG1 are the only known substrates for Vpr-directed depletion through CRL4DCAF1. Here we identify
the endoribonuclease Dicer as a target of HIV-1 Vpr-directed proteasomal degradation through
CRL4DCAF1. We show that HIV-1 Vpr inhibits short hairpin RNA function as expected upon reduction of
Dicer levels. Dicer inhibits HIV-1 replication in T cells. We demonstrate that Dicer also restricts HIV-1
replication in human monocyte-derived macrophages (MDM) and that reducing Dicer expression in
MDMs enhances HIV-1 infection in a Vpr-dependent manner. Our results support a model in which Vpr
complexes with human Dicer to boost its interaction with the CRL4DCAF1 ubiquitin ligase complex and its
subsequent degradation.
& 2013 Elsevier Inc. All rights reserved.
Introduction
Plants and insects were ﬁrst found to employ RNA silencing, a
nucleic acid-dependent immune response, to combat viral infec-
tions. Subsequent work demonstrated that mammals also exploit
RNA silencing as a part of their anti-viral armamentarium
(Andersson et al., 2005; de Vries and Berkhout, 2008; Lecellier
et al., 2005; Lu and Cullen, 2004; Wang et al., 2006). To achieve
RNA silencing, double-stranded RNAs are processed in mammalian
cells by the nuclear endoribonuclease Drosha and exported into
the cytosol. There they are further processed by the endoribonu-
clease Dicer into shorter 21–23 nucleotide duplexes. These are
loaded into the RNA-induced silencing complex (RISC) to confer
speciﬁcity to complementary sequences within messenger RNA.
Assembly with RISC results in either destruction or translational
inhibition of the targeted mRNA.
RNA silencing could restrict virus replication at least three
ways: (1) by direct cleavage of viral RNA which could both destroy
the RNA and process it to speciﬁcally target other viral or cellular
RNA, (2) by cellular miRNA-mediated suppression of transcript
expression or interference with viral processes that employ RNA,
or (3) by use of cellular miRNAs to thwart expression of cellular
proteins required for viral replication. Since most viral infections
do not succumb to these restrictions, many viruses may have
evolved strategies to evade or defeat restrictions imposed through
RNA silencing. Indeed, plant and animal viruses that infect
invertebrates encode suppressors of silencing (SRS). The mechan-
isms that the SRS factors use to inhibit RNA silencing are not well
understood. SRS activity is encoded by a variety of mammalian
viruses and include Ebola virus VP35 protein (de Vries and
Berkhout, 2008), Adenovirus VA RNA I and RNA II (Andersson
et al., 2005; Lu and Cullen, 2004), primate foamy virus type 1 Tas
protein (Lecellier et al., 2005) and hepatitis C core protein (Wang
et al., 2006). This indicates that battles between miRNA restriction
and viral SRSs are taking place in organisms ranging from plants to
mammals.
HIV-1 was among the ﬁrst mammalian viruses shown to
possess SRS activity. Yeung et al. (2005) demonstrated that HIV-
1 hinders miRNA expression in HeLa cells. In the presence of HIV-
1-speciﬁc siRNAs, HIV-1 adopted mutations to break the comple-
mentarity (Boden et al., 2003; Das et al., 2004; Jacque et al., 2002).
Furthermore, HIV-1 encodes a double-stranded RNA trans-
activator response (TAR) loop that binds to, and may sequester
TARBP, a Dicer co-factor that functions as part of the RISC complex
(Bennasser et al., 2006). Other work attributes partial SRS activity
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to Tat (Bennasser et al., 2005; Haasnoot et al., 2007; Qian et al.,
2009; Schnettler et al., 2009), however, the results of another
study conﬂict with these ﬁndings (Lin and Cullen, 2007). Finally,
experimental evidence that miRNAs restrict HIV-1 in otherwise
permissive cells suggests that this virus must encode SRS factors.
This evidence demonstrates that cellular miRNAs target HIV-1
genes (Ahluwalia et al., 2008; Hariharan et al., 2005; Huang et al.,
2007; Omoto et al., 2004; Yeung et al., 2009) or inhibit host factors
that enable HIV replication (Sung and Rice, 2009; Triboulet et al.,
2007). Furthermore, HIV encodes dsRNA regions that could be
targeted by the RNA silencing machinery directly like those found
in primate foamy retrovirus and vesicular stomatitis virus
(Lecellier et al., 2005). Regardless of how miRNAs restrict HIV-1,
it is clear that HIV-1 has evolved to overcome miRNA restriction to
allow effective replication.
Host cells maintain mechanisms aside from miRNA to inhibit
HIV replication and HIV encodes several specialized proteins to
counter them. Some viral defenses act through host cell ubiquitin
ligases. Vif, for example, associates with an elonginBC-Cul5 ubi-
quitin ligase complex to trigger destruction of the host antiviral
factor APOBEC3G (Conticello et al., 2003; Kobayashi et al., 2005;
Marin et al., 2003; Mehle et al., 2004; Sheehy et al., 2003; Stopak
et al., 2003; Yu et al., 2003). In the absence of APOBEC3G
degradation, this cytidine deaminase is incorporated into viral
particles and deaminates viral cytosines to form uracils during the
reverse transcription. APOBEC3G hinders reverse transcription, but
the exact mechanism has not been determined (reviewed in
Wissing et al., 2010). Vpu, another specialized HIV-1 protein,
partners with the SCFβTrCP ubiquitin ligase complex to facilitate
virus release by keeping the cellular protein tetherin/BST-2 from
the cell surface (Gofﬁnet et al., 2009; Gupta et al., 2009; Mangeat
et al., 2009). HIV-2/SIV protein Vpx supports virus replication by
depleting cellular SAMHD1 through the CRL4 ubiquitin ligase
complex (Hrecka et al., 2011; Laguette et al., 2011). SAMHD1 a
deoxynucleoside triphosphate triphosphohydrolase, acts to hinder
retroviral infection by depleting dNTP stores in non-dividing cells
(Goldstone et al., 2011; Hofmann et al., 2012). While HIV-1 Vpr
does not deplete SAMHD1, it aids macrophage infection albeit less
efﬁciently than Vpx (Balliet et al., 1994; Connor et al., 1995;
Heinzinger et al., 1994). HIV-1 Vpr also acts through the CRL4DCAF1
ubiquitin ligase complex to trigger G2 cell cycle arrest, to deplete
cellular UNG2, and to boost expression of NKG2D cell surface
ligand on infected cells. Vpr-mediated enhancement of macro-
phage infectivity was originally attributed to Vpr-mediated trans-
port of the viral pre-integration complex (PIC) into the nucleus
of non-dividing cells (Nie et al., 1998; Popov et al., 1998;
Subbramanian et al., 1998). Other ﬁndings, however, show that
Vpr is not required for nuclear transport of the PIC (Riviere et al.,
2010.; Yamashita and Emerman, 2004). Based on the association of
Vpr with the CRL4 ubiquitin ligase complex we hypothesized that
Vpr, like Vif, Vpu and Vpx commandeers a host ubiquitin ligase
complex to relieve a host cell restriction to infection.
UNG2 and SMUG1 are the only substrates identiﬁed for HIV-1
Vpr-mediated protein degradation through the CRL4 ubiquitin
ligase complex. Neither of these enzymes has been shown to
impact Vpr-mediated G2 cell cycle arrest (Selig et al., 1997). The
role of UNG2 in HIV infection remains unclear. Early work showed
that Vpr brings UNG2 into HIV-1 virions (Chen et al., 2004;
Mansky et al., 2000). More recent work showed that Vpr triggers
degradation of UNG2 through the CRL4 complex to protect the
viral genome against UNG2-mediated processing of APOBEC3G-
mediated damage (Schrofelbauer et al., 2005). Fenard et al. (2009),
however, demonstrated that UNG2 suppresses transcription from
the HIV-1 LTR while Langevin et al. (2009) showed that Vpr
suppresses UNG2 gene transcription. Furthermore, UNG2, in
association with integrase, was shown to be vital for HIV
propagation (Priet et al., 2005). Interestingly (Jones et al. (2010)
linked the requirement for UNG2 to co-receptor usage while other
work showed that UNG2 has little or no effect on HIV replication
(Kaiser and Emerman, 2006; Mbisa et al., 2007). In contrast, Weil
et al. (2013) showed that UNG2 triggers degradation of uracil-
containing HIV-1 cDNA and prevents its integration. Finally,
Vpr-elicited expression of NK-cell ligands (Pham et al., 2011; Ward
et al., 2009) requires both UNG2 and Vpr (Norman et al., 2011).
While working to discover targets for CRL4 action in the
presence of HIV-1 Vpr, we identiﬁed human Dicer as a cellular
Vpr partner. We discovered that it is a substrate for Vpr-mediated
degradation through the CRL4DCAF1 ubiquitin ligase complex.
Probing the impact of the interaction between Dicer and Vpr
on HIV-1 replication in MDMs, we found that HIV infectivity
increased in these cells upon depletion of Dicer. The increase in
infectivity was greater for virus lacking Vpr than for wild-type
virus, indicating that Vpr acts to suppress RNA silencing in MDMs.
Results
HIV-1 Vpr interacts with human Dicer
UNG2 and SMUG1 are the only known targets for Vpr-mediated
proteasomal degradation (Schrofelbauer et al., 2005). Targeting of
each requires the CRL4 ubiquitin ligase complex and both share a
tryptophan-X-X-phenylalanine (WXXF) motif that is required for
UNG2 assembly with Vpr (BouHamdan et al., 1998). We initiated
work to determine whether other cellular proteins are also targets
of Vpr-enhanced proteasomal degradation and whether the WXXF
motif is required for Vpr-mediated targeting.
To discover candidates for Vpr-mediated ubiquitination, we
ﬁrst identiﬁed proteins that co-isolate with Vpr. FLAG-epitope-
tagged HIV-1 Vpr was over-expressed in HEK293T cells from a
transfected expression vector. FLAG–Vpr was isolated from cleared
lysates with FLAG-speciﬁc antibodies conjugated to agarose beads.
Bound proteins were eluted by competition with FLAG peptide.
Analysis of the complete eluate by mass spectrometry identiﬁed
known cellular partners of Vpr, including components of the
CRL4DCAF1 ubiquitin ligase complex and UNG2. Our results also,
for the ﬁrst time, revealed Dicer as a cellular Vpr partner (Fig. 1A).
None of these proteins were detected in our negative control, an
eluate prepared in parallel, originating from cells transfected with
untagged Vpr.
To conﬁrm that human Dicer assembles in a complex with HIV-
1 Vpr, we performed co-immunoprecipitation assays to determine
whether Vpr could be co-isolated with Dicer from lysates of cells
transfected with expression vectors for both. Immunoprecipitation
of Myc-tagged Dicer resulted in the co-puriﬁcation of HIV-1 Vpr
(Fig. 1B). Thus, we conﬁrmed that Dicer and HIV-1 Vpr can
assemble in the same protein complex.
In our co-immunoprecipitation experiments, we consistently
observed lower Dicer levels in lysates from cells co-expressing Vpr
(Fig. 1B). Consequently, less Dicer was immunoprecipitated in the
presence of Vpr than in its absence. Vpr is, of course, known to
engage the CRL4 ubiquitin ligase complex but the substrates of this
complex relevant to HIV infection remain unknown. These obser-
vations led us to hypothesize that the expression of Vpr reduced
Dicer levels by targeting this protein for degradation through the
ubiquitin pathway.
Expression of HIV-1 Vpr triggers depletion of human Dicer both alone
and in the context of an infection
To test our hypothesis that expression of HIV-1 Vpr triggers
degradation of Dicer, we measured Dicer protein levels in the
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absence and presence of Vpr. We saw a substantial decrease in the
level of Myc-tagged Dicer in the presence of Vpr (Fig. 2A), consistent
with our previous observations in the blots of the pre-IP lysates
(Fig. 1B, left). In both sets of experiments we over-expressed Dicer. In
order to rule out the possibility that Vpr-mediated depletion targets
only over- or exogenously expressed proteins, we measured the effect
of Vpr expression on endogenous Dicer levels. Immunoblotting
lysates of mock- or Vpr-transfected cells with Dicer-speciﬁc antibody
revealed a substantial decrease in endogenous Dicer levels in the
presence of Vpr (Fig. 2B). Finally, in order to determine whether Vpr
expressed in the context of an infection is sufﬁcient to cause depletion
of endogenous Dicer, we infected cultures of the SupT1 T cell line and
probed cell lysates for Dicer. Here too we saw depletion of endogen-
ous Dicer (Fig. 2C). As a control we also probed for UNG2, an
established target of HIV-1 Vpr. Like Dicer, UNG2 was depleted only
in cultures infected with HIV-1 encoding Vpr. The capacity of HIV-1
Vpr to reduce cellular Dicer levels was not shared by the Vpr and Vpx
proteins of HIV-2. Infection of SupT1 or HEK293T cells with HIV-2 or
HIV-2 lacking Vpr and/or Vpx did not change Dicer levels, whereas
SAMHD1 was markedly depleted in HEK293T cells infected with HIV-
2 encoding Vpx (Fig. 2 D and E). From this data we conclude that
Dicer depletion is speciﬁc for HIV-1 Vpr like SAMHD1 depletion is for
HIV-2 Vpx.
In summary, our observations show that levels of Dicer,
exogenous or endogenous in origin, are signiﬁcantly decreased in
the presence of Vpr. Furthermore, we observed that expression of
Vpr in the absence of other viral proteins is sufﬁcient to trigger
Dicer depletion, and that the quantities of Vpr present in an
infection are sufﬁcient to mediate this process as well. Based on
the established interaction between Vpr and the CRL4DCAF1 ubi-
quitin ligase complex, we hypothesized that Vpr recruits Dicer
to CRL4DCAF1 for ubiquitination and subsequent proteasomal
destruction.
Fig. 2. Expression of HIV-1 Vpr triggers depletion of human Dicer both alone and in the context of an infection. Lysates of HEK293T cells co-transfected with the indicated
expression vectors were immunoblotted for Dicer and β-actin. Dicer protein levels, relative to the β-actin protein signal, were calculated based on the densitometric analysis
of four separate experiments. A representative immunoblot is shown (A). Please note that in this and all other ﬁgures, error bars represent7SD of the mean. Lysates of
HEK293T cells transfected with either empty vector or HIV-1 FLAG–Vpr expression vector were immunoblotted for endogenous Dicer using antibody speciﬁc for Dicer.
A representative immunoblot is shown, n¼4 (B). Cultures of SupT1 cells were mock infected or infected with HIV-1 (pNL4-3 env(–) nef(–) gfp(+)) or HIV-1 with deleted Vpr
sequences (pNL4-3 env(–) vpr(–) nef(–) gfp(+)) at a MOI¼2. Cells were harvested 48 h after infection for immunoblotting and analysis by ﬂow cytometry. The levels of Dicer,
UNG2, p24, Vpr, and α-tubulin were assessed by western blot (left). The percentage of infected cells was determined by GFP expression as assessed by ﬂow cytometry (right).
The data is representative of n¼2 (C). Cultures of SupT1 cells or HEK293T cells were mock infected or infected with HIV-2 or HIV-2 lacking Vpr or Vpx at equivalent MOIs.
Cells were harvested 48 h after infection for immunoblotting. The levels of Dicer, UNG2, SAMHD1, p27, and α-tubulin were assessed by western blot (D and E).
Fig. 1. HIV-1 Vpr assembles with human Dicer. HEK293T cells were transfected
with expression vector for untagged Vpr or FLAG-epitope tagged Vpr. FLAG-speciﬁc
antibody bound to beads was used to isolate proteins from the cell lysates. Proteins
were eluted from the beads by competition with FLAG peptide and identiﬁed by
mass spectroscopy. Proteins isolated from lysates expressing untagged Vpr served
to identify non-speciﬁcally isolated proteins. The number of peptides identiﬁed in
the negative control (untagged Vpr) and the experimental (FLAG–Vpr) samples are
shown (A). Lysates from HEK293T cells co-transfected with the indicated expres-
sion vectors (EV designates empty expression vector) were immunoblotted directly
or after immunoprecipitation of Myc–Dicer with Myc-speciﬁc antibody. Samples
were resolved by SDS-PAGE and blotted for Dicer or HIV-1 FLAG–Vpr with FLAG-
speciﬁc antibody (B).
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Vpr reduces cellular Dicer levels after translation
Vpr modulates transcription from numerous promoters
(Agostini et al., 1996; Amini et al., 2004; Chowdhury et al., 2003;
Cohen et al., 1990; Cullen, 1991; Fenard et al., 2009; Forget et al.,
1998; Gummuluru and Emerman, 1999; Kino et al., 2005, 2002;
Roux et al., 2000; Sawaya et al., 1998; Sherman et al., 2000; Wang
et al., 1995; Zhu et al., 2003). Langevin et al. (2009) even
demonstrated that Vpr expression speciﬁcally down-modulates
transcription from the UNG2 promoter. We therefore tested
whether Vpr acts to reduce Dicer levels by decreasing transcrip-
tion. Real-time PCR analyses demonstrated that Dicer mRNA levels
do not differ signiﬁcantly in cells expressing Vpr as compared to
those expressing vector alone (Fig. 3A). This ﬁnding indicates that
Vpr does not act as a modulator of Dicer mRNA production.
In order to determine whether Vpr-mediated Dicer depletion
proceeds through proteasomal degradation, we treated cells with
the irreversible proteasome inhibitor epoxomicin prior to lysis.
Inhibition of proteasomal function restored Dicer levels in the
presence of Vpr, suggesting that Vpr decreases Dicer via a
proteasome-dependent pathway (Fig. 3B).
We established that expression of HIV-1 Vpr reduces cellular
Dicer levels in a proteasome-dependent manner, but did not
signiﬁcantly impact levels of Dicer mRNA. In order to conﬁrm that
HIV-1 Vpr impacts Dicer after translation, we measured the stability
of Dicer protein in the presence or absence of HIV-1 Vpr. Cells were
transfected with either an expression vector for FLAG-tagged Vpr or
an empty expression vector. Twenty-four hours later, the cells were
seeded into separate plates. Forty-eight hours after transfection, the
cultures were treated with the translation inhibitor cycloheximide
and then harvested 1, 2.5, 8 and 24 h later. An untreated control was
also harvested for each transfection (T¼0). In Fig. 3C, we show that
the rate of Dicer depletion is greatly enhanced in the presence of
Vpr (T1/2≈2.5 h) compared to our vector control (T1/2424 h).
Together with the previous experiments these data show that Vpr
targets Dicer for depletion after protein translation by dramatically
shortening its half-life.
Vpr-mediated Dicer depletion is not dependent on G2 cell cycle arrest
Since the levels of some proteins are regulated in a cell
cycle-dependent manner, we tested whether the decrease in
Fig. 3. Vpr reduces Dicer levels after protein translation in a manner that is not linked to the cell cycle. HEK293T cells were transfected with either empty expression vector
or expression vector for HIV-1 FLAG–Vpr. Dicer mRNA levels were measured by real-time PCR and were normalized to β-actin mRNA. Quantiﬁcation was calculated using the
Pfafﬂmethod and the relative mean was calculated from three experiments (A). HEK293T cells, transfected with either empty expression vector or expression vector for HIV-
1 FLAG–Vpr, were treated with 1 mM of proteasome inhibitor, epoxomicin, or DMSO. Lysates were prepared as described in Materials and methods and immunoblotted for
exogenous Myc‒Dicer expression. A representative immunoblot is shown, n¼3 (B). HEK293T cells were treated with 25 μg/ml cycloheximide and harvested at the time
points indicated. Lysates were prepared and immunoblotted for endogenous Dicer and α-tubulin expression (C). HEK293T cells were transfected with 1 μg of expression
vector for FLAG–Dicer and 3 μg of empty expression vector or expression vector for the Vpr mutant indicated. Cells were harvested 48 h after transfection and lysates were
probed for Dicer, Vpr, or tubulin, as indicated. The table summarizes the phenotypes of Vpr mutants used (D).
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Dicer levels is directly linked to Vpr-mediated G2 arrest. We
transfected HEK293T cells with an expression vector for FLAG-
epitope-tagged Dicer together with empty expression vector
or expression vector encoding wild-type Vpr or well-
characterized Vpr mutants (Fig. 3D). Among the Vpr species,
wild-type Vpr, Vpr W54R and Vpr R90K caused depletion of
Dicer while Vpr R80A produced partial depletion and Vpr
64LQQAA68 caused no depletion. Wild-type, Vpr W54R and
Vpr 64LQQAA68 cause G2 arrest while Vpr R80A and Vpr R90K
do not (Schrofelbauer et al., 2005; Selig et al., 1997; Sherman
et al., 2000). Thus, both arresting and non-arresting mutants
can trigger depletion or fail to do so, demonstrating that Dicer-
depletion is not dependent on the cell cycle. Additionally, the
Vpr W54R mutant, which does not bind the WXXF-motif of
UNG2 and therefore fails to deplete UNG2 (BouHamdan et al.,
1998; Schrofelbauer et al., 2005), causes Dicer depletion. This,
together with the observation that Dicer has no WXXF motifs
indicates that Vpr is not strictly dependent on this motif for the
recruitment of target proteins.
In summary, Vpr expression causes depletion of cellular Dicer
levels after translation by decreasing Dicer half-life. This pheno-
type was not ampliﬁed by changes in Dicer transcription. The
levels of Dicer could be at least partially restored, in the time-
frame tested, by adding proteasome inhibitor to the culture
media. Finally, the mechanism responsible for accelerated Dicer
turnover does not depend on the ability of Vpr to cause G2 cell
cycle arrest.
Vpr-mediated depletion of Dicer depends on the CRL4DCAF1 ubiquitin
ligase complex
Vpr-directed G2 cell cycle arrest, depletion of UNG2, and
expression of NK-cell ligands have all been linked to the assembly
of Vpr with the CRL4DCAF1 ubiquitin ligase complex. We therefore
tested whether Vpr is required for the recruitment of Dicer to the
CRL4 complex. We expressed, in cultures of HEK293T cells, FLAG
epitope tagged Cul4A alone, together with Myc-Dicer or with both
Myc-Dicer and HA epitope tagged Vpr. We then isolated FLAG‒
Cul4A and probed for the presence of Dicer and Vpr among the co-
isolated proteins. In order to minimize HIV-1 Vpr-mediated
depletion of Dicer in these experiments, we harvested cells at
18 h post-transfection, to capture the proteins as they assembled
but before extensive degradation was observed. In the absence of
FLAG-Cul4A neither Dicer nor Vpr was isolated. Small quantities of
Dicer were co-isolated with FLAG-Cul4A alone, but these were
increased in the presence of HIV-1 Vpr (Fig. 4A). We have
previously shown that UNG2 assembles with and is turned over
through the CRL4DCAF1 complex in the absence of Vpr but that Vpr
enhances this interaction. This observation prompted us to inves-
tigate whether Dicer is also a substrate for the CRL4DCAF1 complex
in the absence of Vpr. To test this, we depleted HEK293T cells of
Cul4A or DCAF1 by siRNA transfection. A non-targeting siRNA was
used as control. Upon depletion of either Cul4A or DCAF1, the
steady state levels of endogenous UNG2 increased, whereas those
of Dicer remained constant (Fig. 4B).
Fig. 4. HIV-1 Vpr-mediated depletion of Dicer relies on the CRL4DCAF1 ubiquitin ligase complex. HEK293T cells were co-transfected with Myc-Dicer, FLAG-Cul4A and HA-Vpr.
FLAG-Cul4A was immunoprecipitated with anti-FLAG beads. Bound proteins were eluted and immunoblotted for Myc-Dicer and HA-Vpr. Myc-Dicer was detected using Dicer
speciﬁc antibody. FLAG-Cul4A and HA-Vpr were detected using antibodies speciﬁc for their respective tags (A). HEK293T cells were transfected with either non-targeting
siRNA or siRNA speciﬁc for Cul4A or for DCAF1. The levels of Dicer, UNG2, DCAF1, Cul4A, and α-tubulin were assessed by immunoblotting with protein-speciﬁc antibodies (B).
HEK293T cells were transfected with either non-targeting siRNA or siRNA speciﬁc for Cul4 (C), DCAF1 (D), or DDB1 (E). Lysates were prepared and corresponding blots were
immunoblotted for endogenous Dicer, Flag–Vpr and α-tubulin. Representative immunoblots are shown.
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Having demonstrated that Vpr enhances the assembly of Dicer
with the CRL4 complex and that the depletion of CRL4 complex
components in the absence of Vpr does not alter steady-state Dicer
levels, we determined whether we could protect Dicer from Vpr
mediated degradation by interfering with CRL4 function. To
ascertain whether the CRL4DCAF1 complex is important for Vpr-
directed depletion of Dicer, we individually depleted three of its
components and probed the impact on Dicer degradation. We
transfected HEK293T cells with siRNA speciﬁc for Cul4, DCAF1, or
DDB1 and then used western blotting to determine whether the
lack of speciﬁc CRL4 components interfered with Vpr-directed
Dicer degradation (Fig. 4C–E, respectively). Treatment with siRNA
speciﬁc for the ubiquitin ligase components, but not with non-
targeting siRNA, restricted the capacity of HIV-1 Vpr to cause Dicer
depletion.
Taken together, these data support a model in which Vpr
assembles with Dicer and the CRL4DCAF1 complex, and that this
complex is required for Vpr-mediated Dicer degradation. Impor-
tantly, Dicer is only the third protein target identiﬁed for Vpr-
directed proteasomal degradation through this ubiquitin ligase
complex and Dicer is the ﬁrst target identiﬁed that lacks a
WXXF motif.
Vpr inhibits shRNA function
Dicer processes double stranded RNAs to products that ulti-
mately lend speciﬁcity to RNA interference. Vpr-directed depletion
of Dicer should thus impede processing of double stranded RNAs.
We therefore investigated the functional consequence of Vpr
expression on Dicer activity. Using a luciferase reporter assay, we
tested whether Vpr suppresses the silencing function of ﬁreﬂy
luciferase-speciﬁc shRNA. We transfected HeLa cells with a ﬁreﬂy
luciferase expression plasmid together with either a shRNA
designed to target ﬁreﬂy luciferase or a scrambled, non-targeting
shRNA as well as a plasmid expressing renilla luciferase to control
for transfection efﬁciency and cell viability. In the absence of Vpr,
the luciferase-directed shRNA reduced luciferase activity by
approximately 80% relative to the scrambled control shRNA
(Fig. 5A). When we co-expressed Vpr, the efﬁcacy of the
luciferase-speciﬁc shRNA was signiﬁcantly decreased, resulting in
increased luciferase expression relative to the vector control
(shLuc/Vector versus shLuc/Vpr in Fig. 5A).
The Vpr Q65R mutant was signiﬁcantly impaired in its capacity to
cause Dicer depletion (Fig. 5B), likely due to its impaired interaction
with DCAF1 (Le Rouzic et al., 2007). Vpr Q65R showed signiﬁcantly
less repression of Dicer activity than wild-type HIV-1 Vpr did,
paralleling the observation that it is less effective at promoting Dicer
depletion. Overall, our results are consistent with a Vpr-speciﬁc
abrogation of shRNA-mediated silencing. These data show that Vpr
can act as a HIV-1-encoded suppressor of RNA silencing (SRS).
Reduction of Dicer levels enhances macrophage infection
in a Vpr-dependent manner
Vpr enhances HIV-1 infectivity in macrophages and Dicer
impairs HIV infectivity in CD4+ T cells. We therefore investigated
how Dicer depletion impacts HIV-1 infection of macrophages and
whether this effect is Vpr-dependent.
We transfected primary human monocyte-derived macro-
phages (MDM) with either an siRNA that speciﬁcally targets
human Dicer or a non-targeting control siRNA. Dicer-speciﬁc
siRNA reduced Dicer protein levels to approximately 20% of those
found in cultures treated with the non-targeting siRNA (Fig. 6A).
We used these cultures to test whether Dicer hinders HIV-1 in
MDMs in the context of a spreading infection. For these experi-
ments we used vpr(+) or vpr(–) forms of NL81A, a HIV-1 which
encodes envelope sequences from the macrophage-tropic BaL
strain in place of the V1–V3 loops of the NL4-3 envelope. The
viruses also contained a GFP gene in place of 5′ nef sequences.
Images of the infected cells were recorded 19 days after infection.
Depletion of Dicer increased infectivity of HIV-1 vpr(–) to a much
greater extent (Fig. 6B panels c and d) than the infectivity of Vpr-
encoding HIV (Fig. 6B panels a and b). Depletion of Dicer, however,
also enhanced infectivity of Vpr-encoding HIV-1 suggesting that
Vpr may not completely deplete Dicer (Fig. 6B panels a and b).
We further tested the impact of Vpr-mediated Dicer depletion
on infection by measuring the quantity of p24 produced by cells
during spreading infections (Fig. 6C). Here, depletion of Dicer
increased the levels of p24 for an infection with HIV-1 vpr(–) to
levels comparable to those of an infection with Vpr-expressing
HIV-1. In this analysis siRNA-mediated depletion of Dicer also
increased the p24 output of infections with Vpr-expressing HIV-1.
However, comparison of the ratios of p24 produced by cultures
transfected with siRNA speciﬁc for Dicer with those transfected
with the non-targeting siRNA control demonstrates that depletion
of Dicer by siRNA had a much greater impact on HIV-1 vpr(–) virus
production than on Vpr-expressing HIV-1 virus production
(Fig. 6D). This suggests that the enhancement mediated by reduc-
tion of Dicer abundance is Vpr-dependent. Our observations
underscore that the effects of Vpr or siRNA-mediated Dicer
depletion on HIV-1 infectivity appear to determine whether a
viable infection can be established.
In order to ascertain whether HIV is inhibited by Dicer before
GFP expression from the provirus, we performed single-round
infections in the presence or absence of Dicer and determined the
number of infected cells using ﬂow cytometry. Two days after
Fig. 5. HIV-1 Vpr suppresses shRNA function. HeLa cells were co-transfected with
ﬁreﬂy and renilla luciferase reporter plasmids as well as with either scrambled or
ﬁreﬂy luciferase-speciﬁc shRNA expression vectors and the indicated HIV-1 Vpr
expression plasmids. Fireﬂy luciferase activity was measured and normalized
against the internal control, renilla luciferase activity. These data were normalized
to the level of luciferase activity in cells transfected with scrambled shRNA, which
was set at 100%. Means were calculated from at least three experiments performed
in duplicate (A). HEK293T cells co-transfected with Myc–Dicer expression vector
along with either empty vector, or expression vector for wild-type HIV-1 FLAG–Vpr
or for HIV-1 FLAG–Vpr Q65R. Lysates were prepared and immunoblotted for
expression of Myc–Dicer, FLAG–Vpr or α-tubulin as indicated. A representative
immunoblot is shown, n¼4 (B).
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transfection with either Dicer-speciﬁc or non-targeting siRNA, we
infected the primary human MDMs with VSV-G pseudotyped,
env(–) HIV-1 that either encodes or fails to encode Vpr. Both of
these viruses have a green ﬂuorescent protein (GFP) reporter gene
in place of nef. Five days after infection, we harvested the cells and
used ﬂow cytometry to determine the fraction of GFP-expressing
cells as a measure of infection. We found that transfection with
Dicer-speciﬁc siRNA signiﬁcantly enhanced infectivity of vpr(–)
HIV-1 but not that of HIV-1 capable of expressing wild-type Vpr
(Fig. 6E).
Consistent with our data from the spreading infections, deple-
tion of Dicer very reproducibly enhanced single-round infection
with vpr(–) HIV-1 in primary human MDMs, albeit modestly. This
suggests that the anti-viral function of Dicer can act on the virus
on its way to establishing a functional provirus in the absence of
Vpr, but leaves open the possibility that Dicer impacts HIV-1 at
other phases of the infection cycle. The observation that depletion
of Dicer does not enhance single-round infection with wild-type
virus, however, suggests that Vpr action is already maximal during
this phase of infection. Our ability to enhance the infectivity of
wild-type virus in spreading infections by depleting Dicer suggests
that Vpr may be less efﬁcient at protecting the virus in another
phase of replication such as during virus production.
Discussion
In this work we showed for the ﬁrst time that HIV-1 Vpr
assembles with Dicer. The primary functional consequence of this
interaction is depletion of Dicer through the CRL4DCAF1 ubiquitin
ligase complex. Indeed we showed that Dicer, Vpr and Cul4 all
assembled into the same protein complex. We further showed that
Vpr-mediated depletion of Dicer interferes with shRNA function.
Importantly, we found that siRNA-mediated depletion of Dicer
boosts HIV-1 infectivity in primary human macrophage cultures
and that this enhancement is signiﬁcantly more pronounced in
infections with vpr(–) virus than with wild-type virus. This of
course suggests that the Vpr associated with the wild-type virus
alleviates the need for Dicer inhibition that is vital for infection
with vpr(–) virus. Of note, Coley et al. (2010) previously showed
that Vpr prevents expression of Dicer upon differentiation of
monocytes. Our work offers an explanation for this ﬁnding. Rather
than inhibiting Dicer production, Vpr triggers its elimination.
Our observations are also consistent with previous reports
showing enhancement of HIV-1 infection after Dicer depletion in
peripheral blood mononuclear cells and the cell lines, Jurkat and
HEK293T (Nathans et al., 2009; Triboulet et al., 2007). Importantly,
these earlier studies did not link the Dicer restriction directly with
a viral protein while our data provides evidence that reducing
Dicer expression offers a greater advantage to the virus in the
absence of Vpr than in its presence. This indicates that Vpr
counteracts the Dicer-dependent restriction. Viral protein-
directed depletion of RNA silencing pathway components has
not been described. Other mechanisms for SRS function rely on
viral protein binding to either RNA or protein targets. The tomato
bushy stunt virus protein p19, targets double-stranded RNA with
2-nucleotide 3′ overhangs to prevent their assembly into the RISC
complex (Scholthof et al., 1995; Silhavy et al., 2002). The ﬂock
Fig. 6. Reduction of Dicer expression in human MDMs enhances HIV-1 infectivity and production in a Vpr-dependent manner. Primary human MDM cultures were
transfected with either non-targeting siRNA or siRNA speciﬁc for Dicer. Forty-eight hours after transfection, lysates were prepared and immunoblotted for endogenous Dicer
and tubulin. A representative immunoblot is shown, n¼2 (A). Primary human MDM cultures were transfected with either non-targeting siRNA or siRNA speciﬁc for Dicer and
infected 24 h after transfection at equivalent MOI with either macrophage-tropic HIV-1 GFP or HIV-1 GFP vpr(–). Infectivity was visualized 19 days after infection by phase
and ﬂuorescence microscopy. Images are shown from a representative experiment. The experiment was performed with primary cells from at least three different donors
and equivalent results were obtained (B). Supernatants from MDM cultures infected in (B) were harvested at days 7, 10 and 14 post-infection and were analyzed for p24 Gag
production by p24 antigen-capture ELISA (C). p24 Gag production data were normalized to the levels of p24 in MDM cultures transfected with non-targeting siRNA to obtain
the fold enhancement of viral production by Dicer siRNA. Means were calculated from p24 analysis of two separate experiments (D). Primary human MDM cultures were
transfected with either non-targeting siRNA or siRNA speciﬁc for Dicer. These were infected 24 h after transfection at an equivalent MOI with either VSV-G pseudotyped
single cycle HIV-1 GFP or HIV-1 GFP vpr(–). Cells were harvested ﬁve days after infection and analyzed by ﬂow cytometry. These data were normalized to the value of cells
transfected with non-targeting siRNA, which was set to 100%. Means were calculated from ﬁve separate experiments using primary cells from ﬁve different donors (E).
L. Casey Klockow et al. / Virology 444 (2013) 191–202 197
house virus B2 protein more generally targets double stranded
RNA to prevent its processing by Dicer (Li et al., 2002). The
cucumber mosaic virus 2b protein interacts with and inhibits
Argonaute in the RISC complex (Zhang et al., 2006). Thus, a variety
of mechanisms are emerging for SRS function and curiously none
appear to be speciﬁc for a particular RNA sequence.
Dicer may not be the only factor that Vpr blocks to aid HIV-1
infection in macrophages. Infection with Vpr-expressing HIV was
more efﬁcient than with vpr(–) HIV-1, even when Dicer was
depleted with siRNA. It is likely that depletion of Dicer resulted
in a smaller improvement of wild-type virus infectivity because
virus-encoded Vpr could deplete at least a portion of cellular Dicer.
Furthermore, while Dicer depletion aided single-round infection
with vpr(–) HIV, we cannot rule out that Vpr-mediated Dicer
depletion can also boost virus production. Since viral RNA is a key
component for both incoming and outgoing virus, it is conceivable
that Dicer function could impact both. Furthermore, it is also
possible that if Dicer was not sufﬁciently depleted in the cultures
to which the corresponding siRNA was applied, that the wild-
type virus had the advantage of carrying Vpr to neutralize
remaining Dicer.
Vpr directs depletion of both UNG2 and SMUG1 proteins, both
of which encode WXXF motifs. The WXXF motif on UNG2 is
critical for its assembly with Vpr (BouHamdan et al., 1998). The
WXXF motif on SMUG1 has not been tested but may perform a
similar function in assembly with Vpr. Addition of this motif to
integrase, allowed its assembly with Vpr (Kulkosky et al., 1999).
Dicer, the third target for Vpr-mediated destruction by CRL4-
DCAF1, does not have a WXXF motif. Furthermore, Dicer was
depleted efﬁciently by the Vpr W54R mutant which fails to bind
UNG2 or to deplete UNG2 (Schrofelbauer et al., 2007). Dicer
therefore is the ﬁrst protein to be identiﬁed that is susceptible to
Vpr-mediated depletion by CRL4-DCAF1 in the absence of the
WXXF motif. This observation suggests that Vpr can ﬂag a range of
proteins for destruction rather than one speciﬁc target.
Previous work showed that Tat can partially suppress Dicer activity
although the signiﬁcance of this ﬁnding has not been fully resolved.
Future experiments comparing the SRS activity of Tat to that of Vpr
will be necessary to determine their respective contributions to
alleviating miRNA restriction, especially in macrophages.
HIV-1 Vpr paralog HIV-2 Vpx does not deplete Dicer. Vpx
enhances macrophage infection albeit more dramatically than
HIV-1 Vpr (Sharova et al., 2008; Srivastava et al., 2008) by
combating antiviral protein SAMHD1 through the CRL4DCAF1 com-
plex. SAMHD1 (Hrecka et al., 2011) also acts as a restriction that
can be overcome by Vpx in monocyte-derived dendritic cells
(Laguette et al., 2011).
While work presented here is focused on the role of the Dicer
interaction with HIV-1 Vpr and its effect on macrophage infection
efﬁciency, this interaction may also impact other Vpr functions. For
example, recent work demonstrated that Vpr expression, trigger-
ing the DNA damage response, up-regulates ULBP-1 and ULBP-2
ligands in infected cells to enhance natural killer cell-mediated
lysis (Richard et al., 2010; Ward et al., 2009). Interestingly,
decreasing Dicer expression can also trigger a DNA damage
response to up-regulate NKGD2 ligands albeit not ULBP-1 or
ULBP-2 (Wu et al., 2011). The factors that determine which NKGD2
ligands are up-regulated in response to DNA damage remain
unclear. Of note, macrophages may not trigger the Dicer-
mediated DNA damage response because Vpr does not activate
ATR in these cells (Zimmerman et al., 2006). Future experiments
examining whether Dicer degradation and Vpr-mediated up-
regulation of ULBP-1 and ULBP-2 are linked could reveal yet
another Vpr function impacted by its interaction with Dicer.
In summary, accumulating evidence has established that the
miRNA pathway can restrict HIV replication in mammalian cells.
Here we identiﬁed Vpr as an HIV-encoded protein that possesses
SRS activity and determined its mechanism for defeating the
miRNA restriction, speciﬁcally triggering destruction of Dicer.
Furthermore, this work identiﬁes a novel substrate of Vpr-
mediated degradation via the CRL4DCAF1 complex. Future studies
to identify miRNAs that are impacted by Vpr expression will offer
new insights into the mechanism of this evolutionarily conserved
antiviral response.
Materials and methods
Ethics statement
All primary human monocyte samples were from de-identiﬁed
donors at the University of Nebraska Medical Center, Omaha, NE.
Our protocol for the use of primary human monocytes was
approved by the Albany Medical College Committee on Research
Involving Human Subjects and granted a category 4 exemption
from consent procedures based on the anonymous nature of the
samples.
Proviral clones and expression plasmids
Macrophage-tropic proviral clones, pNL81A GFP and pNL81A
vpr(–) GFP, were constructed by inserting a BamHI-XhoI fragment
containing eGFP from pNL4-3 GFP env(–) (kindly provided by
Dr. Dana Gabuzda, Dana-Farber Cancer Institute, Boston, MA) into
pNL81A or pNL81A vpr(–) that had been digested with BamHI and
XhoI. The Nef open reading frame was thus replaced with the eGFP
gene. pNL81A and its vpr-deﬁcient counterpart were previously
described (Eckstein et al., 2001; Toohey et al., 1995). FLAG/HA–
Dicer was purchased from Addgene (Addgene plasmid #19881,
provided by Dr. Thomas Tuschl, Rockefeller University, New York
NY). 5′ Myc–Dicer pcDNA3.1 was kindly provided by Dr. Patrick
Provost (Université Laval, Quebec, Canada). The expression vector
for codon-optimized FLAG-epitope tagged Vpr, pcDNA3.1(–)
huFLAG–Vpr was previously described (Wen et al., 2007). The
Vpr mutants tested in Fig. 3 were similarly generated or derived by
PCR-based mutagenesis of the original codon-optimized clones.
The proviruses used in single-round infections, pNL4-3GFP env(–)
and pNL4-3GFP env(–)vpr(–), were kindly provided by Dr. Vicente
Planelles (University of Utah, Salt Lake City, UT). pGL-AN nef(–)GFP,
pGL-St nef(–)GFP pGL-Ec nef(–)GFP and pGL-St/Ec nef(–)GFP origi-
nated as pGL-AN, pGL-St, pGL-Ec and pGL-St/Ec, a kind gift of Dr.
Mikako Fujita, but have GFP inserted in place of nef sequences
upstream of the 3′ LTR.
Cell culture
HEK293T and HeLa cells were maintained in Dulbecco’s mod-
iﬁed Eagle medium (DMEM) supplemented with 10% fetal calf
serum, 2 mM glutamine, 100 units/ml penicillin and 100 μg/ml
streptomycin.
SupT1 cells were maintained in RPMI medium supplemented
with 10% fetal calf serum, 2 mM glutamine, 100 units/ml penicillin
and 100 ug/ml streptomycin.
Human monocytes were obtained from healthy donors at the
University of Nebraska Medical Center, Omaha, NE. Elutriated
monocytes were differentiated for 7 days in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) supplemented with 10% human serum,
and recombinant human macrophage colony-stimulating factor
(rhM-CSF, Cell Sciences, Canton, MA). Cultures were maintained by
replacing one half of the cell culture medium with fresh medium
every 2–3 days. After 7 days in differentiation media, MDMs were
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maintained in DMEM supplemented with 10% human serum
without rhM-CSF.
Immunoprecipitation and Tandem mass spectroscopy analysis
4  106 HEK293T cells were seeded into each of 10, 10 cm
plates. Each culture was transfected, using calcium phosphate,
with 20 μg of pcDNA3.1(–)HIV-1huVpr or pcDNA3.1(–)HIV-1FLAG–
huVpr. Forty-eight hours after transfection the cells were lysed
with 1 ml cold RIPA buffer (25 mM Tris–HCl pH 8.0, 250 mM NaCl,
10 v/v% glycerol, 1 v/v% IGEPAL CA-630, 0.25 w/v% deoxycholic
acid, 2 mM EDTA, 1 mM NaF, 50 mM β–glycerophosphate and
Complete™ protease inhibitor cocktail (Roche)). The lysates were
cleared twice by centrifugation at 10,000  g for 10 min at 4 1C.
The supernatants were incubated with 50 μl of anti-FLAG M2
agarose resin (Sigma–Aldrich) for 2 h at 4 1C with constant rota-
tion. The resin with the bound proteins was washed three times
with lysis buffer. The remaining bound proteins were eluted by
competition with 50 μl of 200 mg/ml FLAG peptide (Sigma–
Aldrich) at room temperature for 10 min. The eluted proteins were
identiﬁed using tandem mass spectroscopy (NextGen Sciences,
Ann Arbor, Michigan).
Immunoprecipitation and immunoblotting
HEK293T cells were transfected using calcium phosphate. Cells
were lysed in ELB buffer (50 mM HEPES pH 7.3, 400 mM NaCl, 0.2%
NP-40, 5 mM EDTA, 0.5 mM DTT) for 15 min and then centrifuged
for 10 min to pellet debris. Clariﬁed supernatants were either
stored as a total cellular lysates or mixed with 50 μl of antibody-
conjugated beads and incubated overnight at 4 1C followed by
competitive elution with peptide corresponding to the epitope tag.
Immunoprecipitates or total cell lysates were resolved by SDS/
PAGE and transferred to PVDF membranes (Millipore). The follow-
ing primary antibodies were used for immunoblotting: c-myc-
speciﬁc monoclonal antibody 9E10 (Stratagene), FLAG-speciﬁc
monoclonal antibody M2 (Sigma-Aldrich), HA-speciﬁc monoclonal
antibody 12CA5 (Roche Applied Science), Dicer-speciﬁc polyclonal
anti-serum (Cell Signaling), Tubulin-speciﬁc monoclonal antibody
N356 (Amersham) and β-actin-speciﬁc monoclonal antibody
(Sigma-Aldrich). The primary antibodies were detected with
corresponding horseradish peroxidase-conjugated secondary anti-
bodies. These were visualized using Immobilon Western horse-
radish peroxidase substrate (Millipore).
Protein levels are reported as relative densitometric intensity
measured by NIH Image J software. Each protein level was
corrected against the corresponding loading control. Means and
standard deviation of means were calculated from at least three
separate experiments.
Proteasome inhibition
HEK293T cells were treated with 1 mM epoxomicin (Sigma–
Aldrich) or an equivalent volume of DMSO for 5–7 h at 37 1C.
Cycloheximide time course
10 cm plates of HEK293T cells were transfected with either
empty vector or with an expression vector for FLAG-epitope-
tagged HIV-1 Vpr. Twenty-four hours later, the cells were replated
into 60 mm dishes. Forty-eight hours later, pre-warmed media
containing 25 μg/ml cycloheximide was added to all cells at
time¼0. Cells were harvested at the indicated time-points and
immediately frozen at −20 1C. Once all samples were harvested,
cells were lysed in ELB buffer (50 mM HEPES pH 7.3, 400 mM NaCl,
0.2% NP-40, 5 mM EDTA, 0.5 mM DTT) for 10 min on ice. Cell
debris was pelleted by centrifugation at 14 K rpm for 10 min.
Supernatants were mixed with 2 Laemmli buffer and boiled to
ensure complete denaturation and lysis. Samples were resolved by
SDS/PAGE and transferred to PVDF membranes (Millipore) for
immunoblotting.
Real-time PCR
Cytoplasmic RNA was isolated from transfected HEK293T cells
using the RNeasy Mini Kit according to manufacturer’s instructions
(Qiagen, Inc., Valencia, CA). DNase-treated RNA was quantiﬁed by
Nanodrop™ spectrophotometer, and 1 μg of RNA was reverse
transcribed using the iScript cDNA synthesis kit, following manu-
facturer’s instructions (BioRad, Hercules, CA). Dicer and β-actin
mRNA was ampliﬁed from 20 ng of cDNA with an Applied
Biosystems 7500 real-time PCR cycler, using SYBR green reagent
(Bio-Rad). The sequence of Dicer- and β-actin-speciﬁc primers is
shown below. These were used at 250 nM or 400 nM concentra-
tions, respectively. Standard curves were established to determine
the ampliﬁcation efﬁciency of each primer set. The efﬁciency for
Dicer was 93.8% and that for β-actin was 93%.
Dicer forward: 5′-CATGGATAGTGGGATGTCAC-3′ (Chendrimada
et al., 2005)
Dicer reverse: 5′-CTACTTCCACAGTGACTCTG-3′ (Chendrimada
et al., 2005)
β-actin forward: 5′-AAAGACCTGTACGCCAACAC-3′
(Chendrimada et al., 2005)
β-actin reverse: 5′-GTCATACTCCTGCTTGCTGAT-3′
(Chendrimada et al., 2005)
The Pfafﬂ method was used to quantify mRNA levels, and Dicer
expression was normalized to β-actin expression.
Short hairpin RNA and siRNA
The ﬁreﬂy luciferase speciﬁc and scrambled luciferase shRNA
vector was constructed using the GeneClip™ U1 Hairpin Cloning
System. The oligonucleotides corresponding to the sequences
shown below were synthesized and annealed with complemen-
tary oligonucleotides, as speciﬁed in manufacturer’s instructions,
and ligated into the expression vector provided. The integrity and
identity of the inserts was conﬁrmed by DNA sequencing.
Luciferase-speciﬁc shRNA:
5′-TCTCAAGTGTTGTTCCATTCCATAAGTTCTCTATGGAATGGAACAA-
CACTTCT-3′
Scrambled luciferase shRNA:
5′-TCTCGATTTTAGCCGTACTTCGTAAGTTCTCTACGAAGTACGGC-
TAAAATCCT-3′
The following siRNAs were purchased from Dharmacon:
Non-targeting control siRNA (CAT# D-001210-02-20)
Dicer: 5′-UGCUUGAAGCAGCUCUGGA(dTdT)-3′
DCAF1: 5′-AUAUGGCCGUUUCCGUAAA(dTdT)-3′
DDB1: 5′-CCCAGUUUCUGCAGAAUGAATA(dTdT)-3′
Cul4 (mix): 5′-CGGCUUCAGCUUUGAGGAGAUA(dTdT)-3′
and 5′-AGGGACUACAUGGAAAGAGAUA(dTdT)-3′
Dicer activity reporter assay
HeLa cells were seeded in 12-well plates and transfected using
FuGene HD (Roche), in triplicate, with 2.5 ng EF-1 renilla luciferase
plasmid, 25 ng of pGL3 control plasmid (Promega), 375 ng of
scrambled or luciferase-speciﬁc shRNA and either 100 ng of vector
or expression plasmid encoding HIV-1 Vpr or HIV-1 VprQ65R. Two
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days after transfection, the cells were harvested in 1 Renilla lysis
buffer (Promega). Lysates were mixed with either Fireﬂy luciferase
assay buffer or Renilla luciferase assay buffer (Promega) and
luciferase activity was measured using a plate reader luminometer.
All samples were normalized to Renilla luciferase activity. Data is
expressed as luciferase activity in luciferase-speciﬁc shRNA trans-
fected cells relative to scrambled shRNA-transfected cells.
Virus preparation and infection
HEK293T cells were transfected with pNL81A HIV-1GFP,
pNL81A HIV-1vpr(–)GFP, pGL-ANnef(–)GFP, pGL-Stnef(–)GFP pGL-
Ecnef(–)GFP or pGL-St/Ecnef(–), using calcium phosphate or
FuGENE HD. Viruses for single round infections were made by
co-transfecting HEK293T cells with viral expression vector and an
expression plasmid for vesicular stomatitis virus G-protein.
Viruses for both spreading and single-round infections were
harvested 48 h after transfection. Supernatants were centrifuged
at 800  g for 5 min to sediment cellular debris. Clariﬁed super-
natants were concentrated with centrifugal ﬁlter columns (Amicon
Ultra 100 K from Millipore) using manufacturer’s protocol. Con-
centrated virus was stored at –80 1C. Viruses were titered on the
GHOST X4/R5 indicator cell line (kindly provided by the NIH AIDS
Research and Reference Reagent Program).
Prior to infections, MDMs that had been differentiated for
7 days were transfected with either non-targeting or Dicer-
speciﬁc siRNA using Lipofectamine 2000 (Invitrogen). Forty-eight
hours after transfection, cells were infected at an equivalent
multiplicity with vpr(+) and vpr(–) viruses. After 5–7 h, cells were
washed twice with PBS and incubated in fresh DMEM supplemen-
ted with 10% human AB serum.
SupT1 cells were incubated with VSV-G pseudotyped vpr(+)
and vpr(–) viruses at a multiplicity of infection of two, as measured
by titration on GHOST indicator cells. After 2 h of incubation, cells
were washed with PBS and resuspended in RPMI media. Forty-
eight hours post-infection, ﬂow analysis was performed on a small
fraction of the cells to analyze infectivity. The rest of the cells were
harvested and lysed. The lysates were separated by SDS/PAGE, and
immunoblotted as previously described.
Single round MDM infections were analyzed, using ﬂow cyto-
metry, ﬁve days after infection. Infected cells were released from
their substrate by incubating cultures for 30 min in a 1:1 solution
of 10 mM EDTA in PBS (pH 7.4) and RPMI containing 20% fetal
bovine serum. Cells were ﬁxed for 30 min at room temperature in
2% formaldehyde and washed twice in PBS. 30,000 events were
recorded on a LSRII ﬂow cytometer (BD Biosciences) and data was
analyzed using FlowJo v7.5 software (Tree Star, Inc., Ashland, OR).
Spreading MDM infections were monitored by ﬂuorescence
microscopy using a Zeiss Axio Observer.Z1 microscope. GFP-
expressing cells were visualized using 488 nm excitation with a
FITC emission ﬁlter set (Zeiss). Images shown were recorded at
19 days after infection.
Virus production was monitored by measuring viral p24gag
protein in cell-free supernatants harvested from cultures at the
speciﬁed time-points. HIV-1 p24 ELISA Assay Kits were used as per
manufacturer’s instructions (AIDS Vaccine Program, National
Cancer Institute (NCI) at Frederick, MD, USA).
Statistical analysis
All analysis was performed using the unpaired Student t test
with a two-tailed distribution.
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